Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

June 30, 2004

Study Completion Date

July 31, 2007

Conditions
Breast Cancer
Interventions
DRUG

Fulvestrant

250 mg \& 500 mg intramuscular injection

Trial Locations (31)

Unknown

Research Site, Little Rock

Research Site, Boston

Research Site, Winchester

Research Site, Albuquerque

Research Site, Hershey

Research Site, Nashville

Research Site, Laredo

Research Site, Innsbruck

Research Site, Salzburg

Research Site, Vienna

Research Site, Barretos

Research Site, Florianópolis

Research Site, Goiamia

Research Site, Porto Alegre

Research Site, Rio de Janeiro

Research Site, Santo André

Research Site, São Paulo

Research Site, Berlin

Research Site, Hanover

Research Site, Magdeburg

Research Site, München

Research Site, Rostock

Research Site, Bangalore

Research Site, Hyderabaad

Research Site, New Delhi

Research Site, Pune

Research Site, Trivandrum

Research Site, Birmingham

Research Site, Bournemouth

Research Site, Dundee

Research Site, Edinburgh

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY